Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the yearCNBC • 07/17/23
Eli Lilly's Alzheimer's treatment shows promise in early stages of disease — but safety concerns remainMarket Watch • 07/17/23
Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMAPRNewsWire • 07/17/23
Lilly drug slows Alzheimer's by 60% for mildly impaired patients, Alzheimer's group saysReuters • 07/17/23
Eli Lilly to expand in obesity drugs with $1.925 billion acquisition of Versanis BioInvezz • 07/14/23
Eli Lilly Unveils A Nearly $2 Billion Deal To Leap Ahead In Weight LossInvestors Business Daily • 07/14/23
Eli Lilly spends up to $1.93B to acquire obesity drug developer VersanisProactive Investors • 07/14/23
Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseasesPRNewsWire • 07/14/23
Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic DiseasesPRNewsWire • 07/14/23
Uninsured Americans pay high costs for an insulin Eli Lilly vowed to price at $25, Sen. Warren saysCNBC • 07/13/23
The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?Investors Business Daily • 07/13/23
Uninsured US patients pay up to $330 for Eli Lilly's $25 insulin, Senator Warren saysReuters • 07/13/23
Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts sayMarket Watch • 07/12/23
EU medicines regulator is reviewing weight-loss drugs Ozempic and Wegovy for risk of suicidal thoughts and self-harmMarket Watch • 07/11/23